Celsion Corporation ( CLSN) today announced that an abstract about the Phase I/II trial of ThermoDox® in Recurrent Chest Wall Cancer (RCW) has been accepted for presentation at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting. The abstract presents the background, rationale, and design of the DIGNITY study which is ongoing and evaluating ThermoDox in combination with hyperthermia in women with recurrent breast cancer on their chest wall. The ASCO Annual Meeting will be held June 4 – 8, 2010 at the McCormick Place Convention Center in Chicago, Illinois.
The abstract, titled "Phase I/II study evaluating the maximum tolerated dose, pharmacokinetics, safety, and efficacy of approved hyperthermia and lyso-thermosensitive liposomal doxorubicin in patients with breast cancer recurrence at the chest wall" will be presented by Nicholas Borys, M.D., Celsion's Chief Medical Officer.
"We are pleased that our study was among those that were accepted providing continued evidence of the medical community's high interest level in ThermoDox, the progress of our clinical program, and our focus on a cancer that is very difficult to treat," commented Michael H. Tardugno, Celsion's President and Chief Executive Officer. "We are grateful for the commitment of our clinical investigators to this important work and look forward to their on-going participation in the DIGNITY trial."
Dr. Borys commented, "Our Phase I/II trial combines ThermoDox with hyperthermia, offering a unique approach to treating patients with difficult loco-regional recurrence of breast cancer at the chest wall. In a separate trial of similar design being conducted at Duke University Medical Center, researchers are reporting convincing evidence of clinical activity. I look forward to the continuation of our trial and the potential to provide an improvement in the standard of care for this devastating disease."
Study shows AI can predict prognosis in triple-negative breast cancer